FORM	4
------	---

Check the	his box if no
longer s	ubject to
Section	16. Form 4 or
Form 5	obligations
may cor	ntinue. See
Instruct	ion 1(b).

- D

(Drint or Ty

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Reich Michael	1 0							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Eirst) OPKO HEALTH, INC., 4400 BISCA BOULEVARD, SUITE 1180	TOTO	3. Date of Earliest Transaction (Month/Day/Year) 03/27/2007					Officer (give title below)Ot	ner (specify belo	w)		
(Street) MIAMI, FL 33137		4. If Amendment, Date Original Filed(Month/Day/Year) 03/29/2007						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security (Instr. 3)	y 2. Transaction Date 2. Transaction Date, if Code 4. Securities Acquire (Month/Day/Year) any (Instr. 8) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	7. Nature of Indirect Beneficial						
		(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock	03/27/2007	J <u>(1)</u>			359,566	Α	\$0	359,566	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1474 (9-02) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
Security	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Warrant (Right to Buy)	\$ 0.6728	03/27/2007		ј <u>(1)</u>		10,901		<u>(4)</u>	03/27/2017	Common Stock	10,901	\$ 0	10,901	D	
Warrant (Right to Buy)	\$ 0.8473	03/27/2007		յ <u>(1)</u>		10,901		<u>(4)</u>	03/27/2017	Common Stock	10,901	\$ 0	10,901	D	
Warrant (Right to Buy)	\$ 1.0466	03/27/2007		<u>ј(1)</u>		10,901		<u>(4)</u>	03/27/2017	Common Stock	10,901	\$ 0	10,901	D	
Stock Option (Right to Buy)	\$ 0.04	03/27/2007		J <u>(1)</u>		62,273		(3)	12/11/2013	Common Stock	62,273	\$ 0	62,273	D	
Stock Option (Right to Buy)	\$ 0.04	03/27/2007		J <u>(1)</u>		25,947		(3)	11/08/2014	Common Stock	25,947	\$ 0	25,947	D	
Stock Option (Right to Buy)	\$ 0.04	03/27/2007		J <u>(1)</u>		103,788		(3)	02/15/2015	Common Stock	103,788	\$ 0	103,788	D	
Stock Option (Right to Buy)	\$ 0.05	03/27/2007		J <u>(1)</u>		155,682		<u>(2)</u>	02/28/2016	Common Stock	155,682	\$ 0	155,682	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Reich Michael OPKO HEALTH, INC. 4400 BISCAYNE BOULEVARD, SUITE 1180 MIAMI, FL 33137	Х						

### Signatures

/s/ Adam Logal, attorney-in-fact	03/19/2008
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.
- (2) 56,219 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.
- (3) These options are fully vested.
- (4) These warrants are currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.